195 results on '"Schreiber-Katz, Olivia"'
Search Results
2. Economic evaluation of Motor Neuron Diseases: a nationwide cross-sectional analysis in Germany
3. Long-term efficacy and safety of nusinersen in adults with 5q spinal muscular atrophy: a prospective European multinational observational study
4. Improvement of muscle strength in specific muscular regions in nusinersen-treated adult patients with 5q-spinal muscular atrophy
5. An observational cohort study on pulmonary function in adult patients with 5q-spinal muscular atrophy under nusinersen therapy
6. Cranial nerve involvement in patients with immune-mediated neuropathy: An observational blink reflex study
7. Metabolic syndrome is common in adults with 5q‐spinal muscular atrophy and impacts quality of life and fatigue.
8. An observational cohort study on impact, dimensions and outcome of perceived fatigue in adult 5q-spinal muscular atrophy patients receiving nusinersen treatment
9. Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study
10. Motor function and treatment satisfaction in adult patients with 5q-spinal muscular atrophy treated with risdiplam: real-world experience from a single neuromuscular center in Germany
11. Executive function is inversely correlated with physical function: the cognitive profile of adult Spinal Muscular Atrophy (SMA)
12. Increased chitotriosidase 1 concentration following nusinersen treatment in spinal muscular atrophy
13. Treatment expectations and patient-reported outcomes of nusinersen therapy in adult spinal muscular atrophy
14. Impact of comorbidities and co-medication on disease onset and progression in a large German ALS patient group
15. Costs of illness in amyotrophic lateral sclerosis (ALS): a cross-sectional survey in Germany
16. Health-Related Quality of Life in Spinal Muscular Atrophy Patients and Their Caregivers—A Prospective, Cross-Sectional, Multi-Center Analysis
17. Cost of illness in Charcot-Marie-Tooth neuropathy: Results from Germany
18. Assessment of disease progression in dysferlinopathy: A 1-year cohort study
19. Differential expression and localization of Ankrd2 isoforms in human skeletal and cardiac muscles
20. Prevalence of Anti-Adeno-Associated Virus Serotype 9 Antibodies in Adult Patients with Spinal Muscular Atrophy
21. Glial fibrillary acidic protein in cerebrospinal fluid of patients with spinal muscular atrophy
22. Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment
23. Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody–Associated Disease
24. Validity and reliability of the German multidimensional fatigue inventory in spinal muscular atrophy
25. Health-related Quality of Life and Satisfaction with German Health Care Services in Patients with Charcot-Marie-Tooth Neuropathy
26. Heterozygous DHTKD1 Variants in Two European Cohorts of Amyotrophic Lateral Sclerosis Patients
27. Glial Fibrillary Acidic Protein in Cerebrospinal Fluid of Nusinersen-Treated Patients with Spinal Muscular Atrophy
28. HMGB1 and RAGE in skeletal muscle inflammation: Implications for protein accumulation in inclusion body myositis
29. The TREAT-NMD DMD Global Database: Analysis of More than 7,000 Duchenne Muscular Dystrophy Mutations
30. Additional file 2 of Increased chitotriosidase 1 concentration following nusinersen treatment in spinal muscular atrophy
31. sj-pdf-1-tan-10.1177_1756286421998902 – Supplemental material for Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapy
32. Executive function is inversely correlated with physical function: the cognitive profile of adult Spinal Muscular Atrophy (SMA)
33. Additional file 1 of Increased chitotriosidase 1 concentration following nusinersen treatment in spinal muscular atrophy
34. Treatment expectations and perception of therapy in adult patients with spinal muscular atrophy receiving nusinersen
35. Informal Caregiving in Amyotrophic Lateral Sclerosis (ALS): A High Caregiver Burden and Drastic Consequences on Caregivers’ Lives
36. Increased Chitotriosidase1 Concentration Following Nusinersen Treatment in Spinal Muscular Atrophy
37. A Nation-Wide, Multi-Center Study on the Quality of Life of ALS Patients in Germany
38. Nusinersen Wearing-Off in Adult 5q-Spinal Muscular Atrophy Patients
39. Cerebrospinal Fluid Parameters in Antisense Oligonucleotide-Treated Adult 5q-Spinal Muscular Atrophy Patients
40. Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapy
41. Additional file 1 of Costs of illness in amyotrophic lateral sclerosis (ALS): a cross-sectional survey in Germany
42. Additional file 2 of Costs of illness in amyotrophic lateral sclerosis (ALS): a cross-sectional survey in Germany
43. Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen.44
44. Cognitive Performance of Patients with Adult 5q-Spinal Muscular Atrophy and with Amyotrophic Lateral Sclerosis
45. An observational cohort study on impact, dimensions and outcome of perceived fatigue in adult 5q-spinal muscular atrophy patients receiving nusinersen treatment
46. Costs of illness in amyotrophic lateral sclerosis (ALS): a cross-sectional survey in Germany
47. Global FKRP Registry: observations in more than 300 patients with Limb Girdle Muscular Dystrophy R9
48. Symptomatic pharmacotherapy in ALS: data analysis from a platform-based medication management programme
49. Assessment of disease progression in dysferlinopathy: a 1-year cohort study
50. Teenage exercise is associated with earlier symptom onset in dysferlinopathy: a retrospective cohort study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.